Workflow
Compass Therapeutics(CMPX)
icon
Search documents
Compass Therapeutics(CMPX) - 2023 Q4 - Annual Report
2024-03-21 13:00
From time to time, we may become involved in litigation or other legal proceedings as part of our ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Item 4. Mine Safety Disclosures. Not applicable. Market Information and Holders of Record Our 2020 Stock Option and Incentive Plan (the "2020 Plan") is the only equity incentive plan approved and adopted by our stoc ...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Newsfilter· 2024-03-21 13:00
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024.Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024. Initiated planning of a Phase 2 monot ...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Newsfilter· 2024-02-28 13:00
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface PD-1CTX-8371 provides enhanced anti-tumor activity relative to approved anti-PD-1 and PD-L1 therapies in a series of in vitro and in vivo experimental settings and modelsThe combination of CTX-8371 and the Compass agonistic anti-CD137 antibody, CTX-471, further increased anti-tumor efficacy in a mouse tumor modelThese ...
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research· 2024-02-08 18:01
Compass Therapeutics, Inc. (CMPX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Ind ...
Compass Therapeutics(CMPX) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 As of November 3, 2023, the registrant had 127,486,326 shares of common stock, $0.0001 par value per share, outstanding. FORM 10-Q | --- | --- | |------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | | | | Commission File Number: | 001-39696 | | COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as | Specifi ...
Compass Therapeutics(CMPX) - 2023 Q2 - Quarterly Report
2023-08-02 16:00
The following discussion of the financial condition and results of operations of Compass Therapeutics, Inc. should be read in conjunction with the financial statements and the notes to those statements included in this Quarterly Report on Form 10-Q for the three and six month periods ended June 30, 2023. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risk, uncer ...
Compass Therapeutics(CMPX) - 2023 Q1 - Quarterly Report
2023-05-03 16:00
FORM 10-Q OR For the transition period from _________________ to _________________ COMPASS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) 80 Guest St., Suite 601 Boston, Massachusetts 02135 (Address of principal executive offices) (Zip Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 mont ...
Compass Therapeutics(CMPX) - 2022 Q4 - Annual Report
2023-03-14 16:00
Medicines can be authorized in the European Union by using either the centralized authorization procedure or national authorization procedures. 42 National authorization procedures. There are also two other possible routes to authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure: Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in on ...
Compass Therapeutics (CMPX) Investor Presentation - Slideshow
2022-12-07 14:55
Corporate Presentation December 2022 SRC DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes ava ...
Compass Therapeutics (CMPX) Investor Presentation - Slideshow
2022-11-23 11:22
Corporate Strategy & Resources - Compass Therapeutics is a clinical-stage biotech company focused on developing antibody therapeutics for cancer[6] - The company's cash runway extends into 2026, with $120 million in cash and marketable securities as of September 2022, plus an $80 million PIPE in November 2022[6] CTX-009 (DLL4 x VEGF-A Bispecific Antibody) - Phase 1a monotherapy showed clinical activity at RP2D dosages (10 and 12.5 mg/kg), with a 19% partial response (PR) rate and a 69% clinical benefit rate (PR + SD) in all patients (n=16)[15] - In a Phase 1b combination study, cholangiocarcinoma patients showed a 50% overall response rate (ORR) and a 75% clinical benefit rate, with a median duration of response of 9.7 months[13] - Interim Phase 2 data in biliary tract cancers (BTC) showed a 42% ORR and a 92% clinical benefit rate (CBR) in patients treated in the second- and third-line settings[38, 54] - A Phase 2/3 randomized BTC study in the US is planned, randomizing 80 patients to CTX-009 + Paclitaxel vs 40 patients to Paclitaxel[55] CTX-471 (CD137 Agonist Antibody) - Phase 1 monotherapy study showed 4 partial responses (PRs) in post PD-1 population: small cell lung cancer, metastatic melanoma, mucosal melanoma, mesothelioma[64, 80] - A Phase 1b study of CTX-471 in combination with Keytruda® (anti-PD-1 therapy) is planned[67] CTX-8371 (PD-1 x PD-L1 Bispecific Antibody) - Preclinical studies showed superior activity to commercial PD-1 and PD-L1 inhibitors, with a unique mechanism of action enhancing T-cell activation[69, 80] - IND submission is targeted for H1 2023[79]